Letter to the editor – the DIABRISK-SL trial: further consideration of age and impact of imputations
Our fellows Efstathia Gkioni and Ketevan Glonti wrote a commentary on the results of a randomised controlled trial (RCT) in Sri Lanka testing the effect of two lifestyle modification programmes of different intensities in participants aged 6-40 with risk factors for T2DM, recently published by Wijesuriya et al. in BMC Medicine.
The commentary was prepared after the careful consideration of the research article for the DIABRISK-SL trial and its protocol: our fellows suggest that further analysis is required to fully understand the potential for benefit, particularly in relation to age, retention and missing data.
Despite this commentary was not accepted for publication on Trials (the Editor explanation for rejection is that the commentary does not contain novel content that would be of broad interest to the broad readership of the journal), we think it raises important points that we would like to share. The full letter to editor is available here.